Literature DB >> 23244098

Metabolic syndrome and colorectal cancer: a cross-sectional survey.

Mojgan Forootan1, Morteza Tabatabaeefar, Mansooreh Yahyaei, Nakisa Maghsoodi.   

Abstract

INTRODUCTION: There is epidemiological evidence indicating that the metabolic syndrome increases the risk of colorectal cancer. Since there is little information about this issue in Iran, the present study was conducted to evaluate prevalence of metabolic syndrome and its components in patients with colorectal cancer.
MATERIAL AND METHODS: This cross-sectional survey involved 200 patients with a new diagnosis of colorectal cancer. Demographic information of patients was collected through the interview with them. Components of metabolic syndrome including fasting glucose serum, triglyceride, high density lipoprotein, blood pressure and waist circumference were measured for all of the patients.
RESULTS: A total of 72 colorectal cancer patients (36%) met metabolic syndrome criteria with rates of 76% for women and 24% for men. BMI in metabolic syndrome patients was higher than other colorectal cancer patients. Disease history including hypertension, diabetes and cardiovascular disease was most frequent in metabolic syndrome patients. Pathological characteristics of colorectal cancer were not significantly associated with the disease.
CONCLUSION: The findings of present study indicated that the prevalence of metabolic syndrome in CRC patients is relatively high. Therefore, further analytical and multi centric studies are needed to better understand the role of metabolic syndrome in development of CRC in Iran. If this association is confirmed in future studies, metabolic syndrome patients should be considered in CRC screening programs.

Entities:  

Mesh:

Year:  2012        PMID: 23244098     DOI: 10.7314/apjcp.2012.13.10.4999

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma.

Authors:  Sebahat Basyigit; Metin Uzman; Ayse Kefeli; Ferdane Pirincci Sapmaz; Abdullah Ozgür Yeniova; Yasar Nazligul; Zeliha Asiltürk
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Da-Hai Dong; Cheng-Tao Han; Cheng-Yuan Gu; Wei-Jie Gu; Xiao-Jian Qin; Li-Jiang Sun; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

Review 3.  Metabolic syndrome and renal cell carcinoma.

Authors:  Gui-Ming Zhang; Yao Zhu; Ding-Wei Ye
Journal:  World J Surg Oncol       Date:  2014-07-29       Impact factor: 2.754

4.  Effect of metabolic syndrome and its components on survival in colorectal cancer: a prospective study.

Authors:  Ali Ahmadi; Mehdi Noroozi; Mohamad Amin Pourhoseingholi; Seyyed-Saeed Hashemi-Nazari
Journal:  J Renal Inj Prev       Date:  2015-03-01

5.  Hypertension and subsequent genitourinary and gynecologic cancers risk: a population-based cohort study.

Authors:  Li-Min Sun; Huang-Tsung Kuo; Long-Bin Jeng; Cheng-Li Lin; Ji-An Liang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

Review 6.  Diabetes-induced mechanophysiological changes in the small intestine and colon.

Authors:  Mirabella Zhao; Donghua Liao; Jingbo Zhao
Journal:  World J Diabetes       Date:  2017-06-15

7.  Cross talk of chromosome instability, CpG island methylator phenotype and mismatch repair in colorectal cancer.

Authors:  Tian-Ming Zhang; Tao Huang; Rong-Fei Wang
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

Review 8.  The Role of Metabolic Factors in Renal Cancers.

Authors:  Jacek Rysz; Beata Franczyk; Janusz Ławiński; Robert Olszewski; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.